Rare adverse events studies
Wednesday, 02 November 2011 15:55
The UK IBD Genetics Consortium is recruiting patients for 4 studies investigating drug-related rare adverse events. They aim to identify clinically useful genetic markers that predict serious drug side effects. Further information can be found at UK IBD Genetics Consortium and in the attached file.
- PRED 4 [ 32 kb ]
Pre-op staging of primary bowel cancer
Monday, 17 October 2011 15:44
The use of PET-CT as an additional imaging modality during pre-operative staging of primary bowel cancer has little evidence to support it, according to research published in Health Technology Assessment. Its use was cost-effective in pre-operative staging of recurrent colon, recurrent rectal and metastatic disease, but not in primary colon or primary rectal cancer. Further information on the research and its conclusions can be found at http://www.hta.ac.uk/news/newsitem141011.shtml?src=rss2.
BSG Research Questions - Overview from Mark Hull
Wednesday, 29 June 2011 15:05
Following the Society-wide consultation about priority research questions to be submitted to NETSCC (the organisation that administers the large NIHR funding streams such as HTA, EME and SDO), the Research Committee (after consultation with the UKCRN Specialty Groups) submitted 12 research questions for appraisal by NETSCC with a view to these questions being used to commission (not fund) future research calls by NIHR. We have just received feedback from NETSCC. The number of votes gained by the 12 questions that were submitted, as well as the feedback given are now detailed on the Research Section of the BSG website
I am pleased to report that one question will be taken forward to the SDO Board for consideration and one question will be reviewed by the HTA Diagnostic panel. There were also two suggestions that research proposals be submitted directly to HTA as Investigator-led bids.
We can learn a lot about how to shape questions for future submissions from the feedback. For example, several questions were felt to be irrelevant to the HTA Programme because the research was not thought to be too ‘early’ and not address the clinical effectiveness of a technology. We will be able to strengthen future submissions in the light of this feedback.
Another bit of good news is that NETSCC also asked to evaluate the other research questions (9) that were not originally requested by NETSCC giving us even more visibility in the NIHR Programmes. The Research Committee will report any further NETSCC feedback in due course.
This is the first time that a Specialist Society has submitted research ideas to NETSCC in such a structured Society-wide manner and I would like to thank all those who helped with the BSG submission especially Julie Solomon and Peter Sime. I hope to see more commissioned calls for NIHR-funded GI and liver research appearing over the next 1-2 years as a consequence. We will certainly be repeating the exercise in the following year.
- Voting outcome and NETSCC feedback [ 21 kb ]
Page 10 of 10